Clown-Free Zone... sorry, no clowns allowed Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: yard_man who wrote (126197)	9/28/2001 1:32:50 PM
From: Earlie	Read Replies (3) of 436258

Tip and gang: A comment or two about a junior medical that might be worth a few speculative bucks. I have completed fairly extensive due diligence and think it represents a decent bet. Company is called Vasogen. Located in Toronto area. Trades on both the TSE (VAS) and the AMEX (MEW). Company has solid patents on its process, which is aimed at quelling the body's inflamatory responses to a broad variety of serious ills. The company's process involves extracting a blood sample from the patient, isolating particular immune system entities, "stressing" those entities, then returning them to the patient's bloodstream. The result of this is that the inflamatory response within the immune system is diminuished dramatically and without consequential (as far as is known) nasty side effects. An interesting thing to note is that many illnesses that do not, on the surface, appear to be inflamation-related in fact are just that, hence the process appears to have a broad variety of applications. The company is sitting on a delightful pile of cash. Insiders have been serious buyers of late (not a typo). A broader cross section of investors are likely to become acquainted with the company and its process this fall as the company will be attending a series of medical and investor conferences during the next few months. The company has attracted an exceptional group of senior medical names to its board of directors and to its advisory group (this is usually a good sign as these guys rarely lend their credentials to companies that are likely to be floperoos). The management team has done a competent job of moving the technology forward. FDA trials are progressing well todate. Risks include the usual broad cross section that one finds associated with any junior company. That list is long and should be kept in mind by any who sniff at this little dickens. Keep in mind as well the fact that most junior medical companies live or die on the apparent time required before an FDA approval might be granted and that bear markets are unusually cruel to junior stocks. Do your own due diligence and do it in earnest. Best, Earlie

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next